Key result
Anti-p305 autoantibodies were detected in only 5% of CHB pregnancies, 13% of unaffected pregnancies with a CHB-sibling, and 0% of unaffected pregnancies with no CHB-sibling, suggesting it is not a robust marker for CHB risk.
Why the study?
Does reactivity to the p305 epitope predict congenital heart block in offspring of anti-SSA/Ro positive mothers?
Observational
Does reactivity to the p305 epitope predict congenital heart block in offspring of anti-SSA/Ro positive mothers?
Absolute Event Rate: 5% vs 0%
Anti-p305 autoantibodies do not appear to be a robust maternal marker for assessing increased risk of congenital heart block during an anti-SSA/Ro pregnancy.
No takes yet. Share an insight, caveat, or question.
Anti-p305 testing should not inform CHB risk stratification in anti-SSA/Ro pregnancies; leaves open identification of reliable biomarkers.
Markham et al. (2015) conducted an observational in Congenital heart block (CHB). Anti-p305 autoantibodies vs. Unaffected pregnancies was evaluated on Detection of anti-p305 autoantibodies (>3 SD above healthy controls). Anti-p305 autoantibodies were detected in only 5% of CHB pregnancies, 13% of unaffected pregnancies with a CHB-sibling, and 0% of unaffected pregnancies with no CHB-sibling, suggesting it is not a robust marker for CHB risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: